ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The pharmaceutical giant Pfizer is pulling its small-molecule drug for mild-to- moderate symptoms of sickle cell anemia, which had been granted accelerated approval. The European Medicines Agency (EMA) raised concerns in July after deaths of participants in the follow-up clinical trials of Oxbryta. The EMA scheduled a meeting last month to discuss “emerging data” about the drug, but Pfizer decided to pull the drug in all markets before that meeting took place.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter